Major stock indexes declined Thursday as investors digested several big tech earnings reports and awaited more after the ...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to ...

Cipla has now entered into obesity Market with a partnership with Eli Lilly for Tirzepatide (GLP-1) is exclusive to the ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

NEW YORK (AP) — The U.S. stock market is pulling back from its record heights on Thursday, as Wall Street sifts through mixed ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

Discover Eli Lilly’s Q3 2025 earnings highlights: record 54% revenue growth, new product approvals, raised guidance, and global expansion.

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

Dow Jones Top Company Headlines at 11 AM ET: Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera | Mounjaro ... Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

Dow Jones Top Company Headlines at 9 AM ET: Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings | Novo ... Eli Lilly reported higher profit and raised its outlook on surging demand for its ...